The brand is now expanding its U.S. presence through its own direct-to-consumer (DTC) website, providing consumers with a new way to discover and purchase VALITIC™ products while enabling a direct relationship with customers. The initial launch will allow B.I. Sky Global to optimize the platform and customer experience ahead of a larger marketing and promotional campaign planned for the 2026 holiday shopping season.
The DTC platform complements VALITIC™'s Amazon business and supports B.I. Sky Global's broader strategy to build a scalable, multi-channel U.S. consumer wellness business.
"Launching our own website gives us a direct connection with VALITIC™ customers and an additional channel for growth," said Roni Kamhi, CEO of B.I. Sky Global & COO of Innocan "We are using this initial phase to optimize the platform and prepare for a larger-scale holiday launch."
VALITIC™ products are available now at: ValiticBeauty.com
Iris Bincovich, CEO of Innocan Pharma, added: "Building a direct-to-consumer channel alongside Amazon reduces reliance on a single marketplace and gives us more ways to grow sales. Combined with the traction VALITIC™ has already achieved, we believe this expanded distribution strategy provides a strong foundation for continued growth in the U.S. market as we head into the holiday season."
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60%-owned subsidiary, B.I. Sky Global Ltd., which focuses on advanced, targeted online sales.
www.innocanpharma.com
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 516-210-4025
+972-54-3012842
+44 20 3769 9377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, statements regarding the planned holiday-season launch and related marketing and promotional initiatives, the expected contribution of the direct-to-consumer channel alongside Amazon and other online retail channels, and the anticipated growth of the VALITIC™ brand in the U.S. market, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
SOURCE Innocan Pharma Corporation
Share this article